Ketamine and Magnesium for Refractory Neuropathic Pain A Randomized, Double-blind, Crossover Trial

被引:0
|
作者
Pickering, Gisele [1 ,2 ]
Pereira, Bruno [3 ]
Morel, Veronique [1 ]
Corriger, Alexandrine [1 ]
Giron, Fatiha [1 ]
Marcaillou, Fabienne [4 ]
Bidar-Beauvallot, Assiya [4 ]
Chandeze, Evelyne [4 ]
Lambert, Celine [3 ]
Bernard, Lise [5 ]
Delage, Noemie [4 ]
机构
[1] Univ Hosp Clermont Ferrand, Clin Pharmacol Dept, Inserm, CIC 1405, F-63000 Clermont Ferrand, France
[2] Clermont Auvergne Univ, Inserm 1107, F-63000 Clermont Ferrand, France
[3] Univ Hosp Clermont Ferrand, Clin Res & Innovat Dept, F-63000 Clermont Ferrand, France
[4] Univ Hosp Clermont Ferrand, Assessment & Treatment Pain Ctr, F-63000 Clermont Ferrand, France
[5] Univ Hosp Clermont Ferrand, Clin Res Temporary Authorizat Dept, F-63000 Clermont Ferrand, France
关键词
SF-36 HEALTH SURVEY; INTRAVENOUS KETAMINE; MORPHINE; SULFATE; QUESTIONNAIRE; METAANALYSIS; VALIDATION; MANAGEMENT; THERAPY;
D O I
10.1097/ALN.0000000000003327
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Ketamine is often used for the management of refractory chronic pain. There is, however, a paucity of trials exploring its analgesic effect several weeks after intravenous administration or in association with magnesium. The authors hypothesized that ketamine in neuropathic pain may provide pain relief and cognitive-emotional benefitversusplacebo and that a combination with magnesium may have an additive effect for 5 weeks. Methods: A randomized, double-blind, crossover, placebo-controlled study (NCT02467517) included 20 patients with neuropathic pain. Each ketamine-naive patient received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulfate (3g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion. Secondary endpoints included pain (at 7, 15, 21 and 28 days) and health-related, emotional, sleep, and quality of life questionnaires. Results: Daily pain intensity was not significantly different between the three groups (n = 20) over 35 days (mean area under the curve = 185 +/- 100, 196 +/- 92, and 187 +/- 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively,P= 0.296). The effect size of the main endpoint was -0.2 (95% CI [-0.6 to 0.3];P= 0.425) for ketamineversusplacebo, 0.2 (95% CI [-0.3 to 0.6];P= 0.445) for placeboversusketamine/magnesium and -0.4 (95% CI [-0.8 to 0.1];P= 0.119) for ketamineversusketamine/magnesium. There were no significant differences in emotional, sleep, and quality of life measures. During placebo, ketamine, and ketamine/magnesium infusions, 10%, 20%, and 35% of patients respectively reported at least one adverse event. Conclusions: The results of this trial in neuropathic pain refuted the hypothesis that ketamine provided pain relief at 5 weeks and cognitive-emotional benefitversusplacebo and that a combination with magnesium had any additional analgesic effect.
引用
收藏
页码:154 / 164
页数:11
相关论文
共 50 条
  • [31] Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial
    Rigo, Flavia Karine
    Trevisan, Gabriela
    Godoy, Maria C.
    Rossato, Mateus F.
    Dalmolin, Gerusa D.
    Silva, Mariane A.
    Menezes, Mirian S.
    Caumo, Wolnei
    Ferreira, Juliano
    PAIN PHYSICIAN, 2017, 20 (03) : 207 - 215
  • [32] A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia
    Goldenberg, D
    Mayskiy, M
    Mossey, C
    Ruthazer, R
    Schmid, C
    ARTHRITIS AND RHEUMATISM, 1996, 39 (11): : 1852 - 1859
  • [33] Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication
    Markman, John D.
    Frazer, Maria E.
    Rast, Shirley A.
    McDermott, Michael P.
    Gewandter, Jennifer S.
    Chowdhry, Amit K.
    Czerniecka, Kate
    Pilcher, Webster H.
    Simon, Lee S.
    Dworkin, Robert H.
    NEUROLOGY, 2015, 84 (03) : 265 - 272
  • [34] A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling
    Hollander, E
    DeCaria, CM
    Finkell, JN
    Begaz, T
    Wong, CM
    Cartwright, C
    BIOLOGICAL PSYCHIATRY, 2000, 47 (09) : 813 - 817
  • [35] THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL
    SILVA, SRB
    VIANA, PCF
    LUGON, NV
    HOETTE, M
    RUZANY, F
    LUGON, JR
    NEPHRON, 1994, 67 (03): : 270 - 273
  • [36] Glycopyrrolate for sialorrhea in Parkinson disease A randomized, double-blind, crossover trial
    Arbouw, M. E. L.
    Movig, K. L. L.
    Koopmann, M.
    Poels, P. J. E.
    Guchelaar, H. -J.
    Egberts, T. C. G.
    Neef, C.
    van Vugt, J. P. P.
    NEUROLOGY, 2010, 74 (15) : 1203 - 1207
  • [37] Amitriptyline in neuropathic cancer pain in patients on morphine therapy: A randomized placebo-controlled, double-blind crossover study
    Mercadante, S
    Arcuri, E
    Tirelli, W
    Villari, P
    Casuccio, A
    TUMORI, 2002, 88 (03) : 239 - 242
  • [38] Randomized, double-blind, controlled trial of a combination of alpha-lipoic acid and pregabalin for neuropathic pain: the PAIN-CARE trial
    Gilron, Ian
    Robb, Sylvia
    Tu, Dongsheng
    Holden, Ronald R.
    Jackson, Alan C.
    Duggan, Scott
    Milev, Roumen
    PAIN, 2024, 165 (02) : 461 - 469
  • [39] Effects of botulinum toxin B on refractory detrusor overactivity: A randomized, double-blind, placebo controlled, crossover trial
    Ghei, M
    Maraj, BH
    Miller, R
    Nathan, S
    O'Sullivan, C
    Fowler, CJ
    Shah, PJR
    Malone-Lee, J
    JOURNAL OF UROLOGY, 2005, 174 (05): : 1873 - 1877
  • [40] Efficacy of deep rTMS for neuropathic pain in the lower limb: a randomized, double-blind crossover trial of an H-coil and figure-8 coil
    Shimizu, Takeshi
    Hosomi, Koichi
    Maruo, Tomoyuki
    Goto, Yuko
    Yokoe, Masaru
    Kageyama, Yu
    Shimokawa, Toshio
    Yoshimine, Toshiki
    Saitoh, Youichi
    JOURNAL OF NEUROSURGERY, 2017, 127 (05) : 1172 - 1180